Glen Clova: Fighting autoimmunity with cytokine-carrying virus-like particles

Glen Clova aims to treat autoimmune and allergic diseases by immunizing patients against high levels cytokines. The company believes its approach of attaching cytokine antigens to virus-like particles will beat standard cytokine-targeting biologics on dosing frequency, safety and price.

The biotech, which raised a £4.4 million ($4.9 million) seed round last year, expects to enter IND-enabling studies by year-end...